+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

Liver Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Therapeutics - Global Strategic Business Report

  • Report
  • October 2025
  • 287 Pages
  • Global
From
From
From
HER2-Positive Gastric Cancer - Global Strategic Business Report - Product Thumbnail Image

HER2-Positive Gastric Cancer - Global Strategic Business Report

  • Report
  • October 2025
  • 281 Pages
  • Global
From
Throat Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Throat Cancer Therapeutics - Global Strategic Business Report

  • Report
  • October 2025
  • 267 Pages
  • Global
From
Oncolytic Virotherapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virotherapy - Global Strategic Business Report

  • Report
  • October 2025
  • 243 Pages
  • Global
From
Gastric Cancer - Global Strategic Business Report - Product Thumbnail Image

Gastric Cancer - Global Strategic Business Report

  • Report
  • October 2025
  • 582 Pages
  • Global
From
Personalized Cancer Medicines - Global Strategic Business Report - Product Thumbnail Image

Personalized Cancer Medicines - Global Strategic Business Report

  • Report
  • October 2025
  • 267 Pages
  • Global
From
Anti-Inflammatory Drugs - Global Strategic Business Report - Product Thumbnail Image

Anti-Inflammatory Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 488 Pages
  • Global
From
Metastatic Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Metastatic Cancer Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 377 Pages
  • Global
From
Oncolytic Virus Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virus Immunotherapy - Global Strategic Business Report

  • Report
  • October 2025
  • 383 Pages
  • Global
From
From
From
Adenoid Cystic Carcinoma - Global Strategic Business Report - Product Thumbnail Image

Adenoid Cystic Carcinoma - Global Strategic Business Report

  • Report
  • October 2025
  • 386 Pages
  • Global
From
From
Angiosarcoma Treatment - Global Strategic Business Report - Product Thumbnail Image

Angiosarcoma Treatment - Global Strategic Business Report

  • Report
  • October 2025
  • 390 Pages
  • Global
From
From
From
Oncolytic Virus Therapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virus Therapy - Global Strategic Business Report

  • Report
  • October 2025
  • 483 Pages
  • Global
From
PARP Inhibitor Biomarkers - Global Strategic Business Report - Product Thumbnail Image

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • Report
  • October 2025
  • 278 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more